| 摘要 |
<p>Use of a composition (A) that inhibits interaction between plexin-A1 and DAP-12 for preparing a pharmaceutical for treatment and prevention of inflammatory, autoimmune or bone resorption diseases, is new. Independent claims are also included for: (1) kit for identifying compounds that inhibit interaction between plexin-A1 (I) and DAP-12 (II) activity in a cell; (2) kit for identifying compounds that inhibit interaction between (I) and Trem-2 (III) activity in a cell; (3) kit for identifying compounds that inhibit interaction between (II) and (III) in a cell; (4) antibody, or its binding site, that binds to (I), (II) or (III), or their fragments; and (5) biotherapeutic composition for treating the specified diseases that contains (I), (II), (III) or their fragments. ACTIVITY : Osteopathic; Antiarthritic; Antiinflammatory; Antiarteriosclerotic; Dermatological; Antiasthmatic; Antiulcer; Antipsoriatic; Immunosuppressive; Antidiabetic; Antirheumatic; Analgesic; Cerebroprotective; Cardiant; Nephrotrophic; Antibacterial; Vasotropic. No biological data given. MECHANISM OF ACTION : Inhibiting interaction between any two of plexin-A1; DAP-12 and Trem-2, leading to a reduction in cytokine formation. Plexin-A1 (implicated in both the immune response and bone homeostasis) is associated with Trem-2 (a trigger receptor on myeloid cells), so links the semaphorin signalling pathway with DAP-12 (an adaptor protein carrying the immuno-receptor, tyrosine-based activation motif).</p> |
